uploads///MDTs CVG

A Look at Medtronic’s Cardiac & Vascular Group’s Revenue Streams

By

Dec. 13 2018, Updated 9:00 a.m. ET

Cardiac & Vascular Group

Medtronic’s Cardiac & Vascular Group consists of the Cardiac Rhythm & Heart Failure (or CRHF), the Coronary & Structural Heart (or CSH), and Aortic, Peripheral & Venous (or APV) segments.

Article continues below advertisement

Cardiac Rhythm & Heart Failure segment trends

Medtronic’s (MDT) Cardiac Rhythm & Heart Failure segment generated revenues of $1.47 billion in the second quarter of fiscal 2019. The Cardiac Rhythm & Heart Failure segment revenues remained nearly flat in the second quarter of fiscal 2019 compared to the second quarter of fiscal 2018.

The Cardiac Rhythm & Heart Failure segment generated revenues of $2.9 billion over the first six months of fiscal 2019, reflecting ~1% YoY growth.

The growth in sales of TYRX absorbable antibacterial envelope, Mirca, and Azure primarily pushed the revenue growth of the Cardiac Rhythm & Heart Failure segment.

Coronary & Structural Heart segment revenue trends

Medtronic’s (MDT) Coronary & Structural Heart segment generated revenues of $906.0 million in the second quarter of fiscal 2019 compared to $854.0 million in the second quarter of fiscal 2018, reflecting ~6% YoY growth. The Coronary & Structural Heart segment generated net revenues of $1.8 billion over the first half of fiscal 2019 compared to $1.7 billion in the same period the prior year, reflecting ~9% YoY growth.

The solid growth in sales of TAVR (transcatheter aortic valve replacement), DES, guide catheters and coronary balloons primarily contributed to the revenue growth of Medtronic’s Coronary & Structural Heart segment.

Aortic, Peripheral & Venous segment trends

Medtronic’s Aortic, Peripheral & Venous segment generated revenues of $948.0 million over the first half of fiscal 2019 compared to $891.0 million in the same period the prior year, reflecting ~6% YoY growth.

Aortic, Peripheral & Venous segment reported revenues of $480.0 million in the second quarter of fiscal 2019 compared to $452.0 million in the second quarter of 2018, reflecting ~6% YoY growth.

The high demand for VenaSeal primarily contributed to the revenue growth of Medtronic’s Aortic, Peripheral & Venous segment.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.